Core Viewpoint - Pumen Technology (688389.SH) reported a decline in revenue and net profit for the fiscal year 2025, attributed to domestic healthcare payment reforms and price adjustments in some products [1] Financial Performance - The company achieved total operating revenue of 1.038 billion yuan, a year-on-year decrease of 9.60% [1] - The net profit attributable to the parent company was 186 million yuan, down 46.12% year-on-year [1] - The net profit attributable to the parent company after deducting non-recurring gains and losses was 166 million yuan, a decrease of 49.28% year-on-year [1] Business Operations - Domestic business revenue declined compared to the same period last year due to industry policy impacts [1] - International marketing business showed stable growth, with ongoing efforts in regional coverage, localized services, and market access [1] - The company remains focused on its core business strategy, emphasizing in vitro diagnostics, clinical medicine, dermatology aesthetics, and consumer health markets [1] - Continuous investment in R&D and marketing is maintained to enrich product offerings and expand market reach [1]

Core Viewpoint - The company, Pumen Technology (688389.SH), clarified that its main business does not include the brain engineering sector, focusing instead on in vitro diagnostics, clinical medicine, skin aesthetics, and consumer health [2] Summary by Relevant Categories Business Scope - The company's primary operations encompass in vitro diagnostics, clinical medicine, skin aesthetics, and consumer health [2] Investor Interaction - An investor inquired whether the company's medical device business falls under the brain engineering sector, to which the company responded that it currently does not engage in this area [2]